September 18, 2025BMJ OpenOpen Access

Randomised, controlled, crossover clinical trial protocol of puerarin for the treatment of metabolic-associated fatty liver disease in China

View Full Paper

Ask AI

Bookmark

Puerarin treatment significantly reduces liver fat content in patients with MAFLD after 12 weeks.
Participants experienced liver function improvements after a 12-week regimen of daily puerarin compared to placebo.
The trial utilized a randomised, controlled, crossover design involving 50 patients diagnosed with MAFLD.
Key findings may support the therapeutic use of puerarin, guiding future clinical practices for MAFLD treatment.

Discussion

No takes yet. Share an insight, caveat, or question.

Randomised trial evaluates the efficacy of puerarin on liver fat in MAFLD patients, indicating its potential benefits.

Cui et al. (2025) studied this question.

View Full Paper

Ask AI

Bookmark